VistaGen Therapeutics Inc. (NASDAQ: VTGN) Committed to Developing New Generation of Medicines with Potential to Treat Rising Mental Health Challenges from Depression

February 18, 2021 09:24:17
  • Mental health experts note growing concern over impact of COVID-19 on nation’s mental health
  • Compounding stress could have serious health, social consequences
  • VTGN offers new hope to those dealing with depression disorders

A new survey from the American Psychological Association (“APA”) shines a spotlight on the growing concern about the impact of the global pandemic on the nation’s mental health (https://ibn.fm/ukaIx). These rising numbers, as well as the treatment for mental health illness and disorders, is of great concern to VistaGen Therapeutics (NASDAQ: VTGN), a biopharmaceutical company committed to developing a new generation of medications that goes beyond the standard of care for anxiety and depression.

Nearly eight in ten adults (78%) report that the coronavirus pandemic is a significant source of stress in their lives, while three in five (60%) say the number of issues America faces is overwhelming to them, according to the…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to VTGN are available in the company’s newsroom at https://ibn.fm/VTGN

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.